TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Baxter International ( (BAX) ) is now available.
On November 5, 2025, Alok Sonig informed Baxter International of his decision to resign from his role as Executive Vice President and Group President, Pharmaceuticals, effective December 1, 2025, to join another healthcare company.
The most recent analyst rating on (BAX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
Baxter International’s overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges, including high leverage and negative profitability, which are reflected in its valuation metrics. Technical indicators suggest a bearish trend, further weighing on the stock’s outlook. While the earnings call provides some positive guidance, the overall risks and challenges overshadow potential growth opportunities.
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Average Trading Volume: 6,923,766
Technical Sentiment Signal: Sell
Current Market Cap: $9.12B
For detailed information about BAX stock, go to TipRanks’ Stock Analysis page.